SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI
CCSI 21.31-5.2%12:37 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Nick who wrote (2778)6/10/1998 10:55:00 PM
From: R. M. Rosenthal   of 5736
 
This is the nitty gritty folks. Open up your eyes and pay attention.
This is the TRUTH. The truth is stronger than the bullshit here and the perpetrators will reap what they have sown.

<- Previous
Next ->
Message 2472 of 2483
Reply

MANUEL ASENSIO WILLFULLY
OMITS CRUCIAL DATA
Tabadoa1
Jun 10 1998
10:11PM EDT

FROM HIS "RESEARCH REPORT".THE POTENTIAL EARNINGS MODEL FOR
CHROMATICS,AS APPARENTLY EVERYONE BUT MR.ASENSIO KNOWS,IS BASED ON A
PER TEST FORMULA,NOT ON THE SALE OF THE DEVICES.THE PER TEST DATA IS
READILY AVAILABLE BUT WAS GLARINGLY IGNORED BY ASENSIO.DID ASENSIO
CONTACT CHROMATICS PRIOR TO PUBLISHING HIS REPORT?NO.THE COLORMATEIII
IS THE ONLY FDA APPROVED BLOOD TEST EQUIVILENT DEVICE FOR BILIRUBIN IN
EXISTENCE ON THE PLANET.THIS SINGULAR MOST IMPORTANT FACT OF ALL WAS
PURPOSELY OMITTED BECAUSE IT COMPLETLY INVALIDATES ASENSIO'S ENTIRE
PREMISE FOR RECOMMENDING A SHORT SELL OF THE STOCK.HIS REFUTATIONS OF
CCSI's PATENT VALUES ARE COMPLETELY FALSE AND MISLEADING BECAUSE OF
THESE OMISSIONS.ALL CONCERNED PARTIES MUST DEMAND AN EXPLANATION FOR
THIS BLATENT FALSEHOOD BEING PASSED OFF AS FACT.HOW DO YOU EXPLAIN
THESE OMISSIONS MR.ASENSIO?WHY ARE YOU WILLFULLY MISLEADING
INVESTORS,MAJOR MEDIA,AND SECURITIES REGULATORS?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext